PE20140845A1 - Formulaciones parenterales de vacunas contra los norovirus - Google Patents

Formulaciones parenterales de vacunas contra los norovirus

Info

Publication number
PE20140845A1
PE20140845A1 PE2014000054A PE2014000054A PE20140845A1 PE 20140845 A1 PE20140845 A1 PE 20140845A1 PE 2014000054 A PE2014000054 A PE 2014000054A PE 2014000054 A PE2014000054 A PE 2014000054A PE 20140845 A1 PE20140845 A1 PE 20140845A1
Authority
PE
Peru
Prior art keywords
genogroup
norovirus
virus
vlp
capsid protein
Prior art date
Application number
PE2014000054A
Other languages
English (en)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140845(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of PE20140845A1 publication Critical patent/PE20140845A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION DE VACUNA QUE COMPRENDE: A) PARTICULAS TIPO VIRUS (VLP) DEL GENOGRUPO I DE NOROVIRUS DEL VIRUS NORWALK EN UNA CANTIDAD DE HASTA 150 uG QUE COMPRENDE UNA PROTEINA DE LA CAPSIDE DERIVADA DE UNA CEPA VIRAL DEL GENOGRUPO I; B) PARTICULAS TIPO VIRUS (VLP) DEL GENOGRUPO II DE NOROVIRUS GENERADAS A PARTIR DE LA EXPRESION DE UNA SECUENCIA CONSENSO DEL GENOGRUPO II DE NOROVIRUS EN UNA CANTIDAD DE HASTA 150 uG QUE COMPRENDE UNA PROTEINA DE LA CAPSIDE DERIVADA DE UNA CEPA VIRAL DEL GENOGRUPO II; C) DOS ADYUVANTES TALES COMO MONOFOSFORIL LIPIDO A E HIDROXIDO DE ALUMINIO; Y D) UNA SOLUCION AMORTIGUADORA TAL COMO L-HISTIDINA, IMIDAZOL, ACIDO SUCCINICO, TRIS Y ACIDO CITRICO. DICHA COMPOSICION INDUCE UN AUMENTO DE TRES VECES EL TITULO DE ANTICUERPOS ESPECIFICOS DE NOROVIRUS EN SUERO EN COMPARACION CON EL TITULO ANTES DE SU ADMINISTRACION
PE2014000054A 2011-07-11 2012-07-11 Formulaciones parenterales de vacunas contra los norovirus PE20140845A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
PE20140845A1 true PE20140845A1 (es) 2014-08-03

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000054A PE20140845A1 (es) 2011-07-11 2012-07-11 Formulaciones parenterales de vacunas contra los norovirus

Country Status (29)

Country Link
US (5) US9801934B2 (es)
EP (3) EP2731621B1 (es)
JP (2) JP6208659B2 (es)
KR (1) KR102096937B1 (es)
CN (3) CN103874507A (es)
AU (2) AU2012282658B2 (es)
BR (1) BR112014000656A2 (es)
CA (1) CA2841356C (es)
CL (1) CL2014000082A1 (es)
CR (2) CR20190540A (es)
DK (1) DK3299030T3 (es)
DO (2) DOP2014000004A (es)
EA (3) EA202090699A3 (es)
EC (1) ECSP14013201A (es)
ES (2) ES2656527T3 (es)
GE (1) GEP201706668B (es)
HK (3) HK1198136A1 (es)
IL (1) IL230356B (es)
MA (1) MA35414B1 (es)
MX (1) MX356586B (es)
MY (1) MY170746A (es)
PE (1) PE20140845A1 (es)
PH (1) PH12018501515B1 (es)
PL (2) PL2731621T3 (es)
SG (1) SG10201605644WA (es)
TN (1) TN2014000008A1 (es)
UA (1) UA117732C2 (es)
WO (1) WO2013009849A1 (es)
ZA (2) ZA201401012B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174845A1 (en) 2006-09-29 2011-10-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
WO2013009849A1 (en) 2011-07-11 2013-01-17 Ligocyte Pharmaceuticals, Inc. Parenteral norovirus vaccine formulations
SG11201602585XA (en) 2013-10-03 2016-05-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
JP6556632B2 (ja) 2013-12-16 2019-08-07 武田薬品工業株式会社 マイクロニードル
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
JP2020519666A (ja) * 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定性のウイルス含有組成物
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2021140524A1 (en) 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
EP4317436A1 (en) 2021-03-29 2024-02-07 Denka Company Limited Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus
JP2024519800A (ja) 2021-05-21 2024-05-21 タケダ ワクチン，インコーポレイテッド 固体組成物、フリーズドライ方法およびガラスバイアル
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) 1991-03-25 1992-10-01 Genelabs Incorporated NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
WO1993021325A1 (en) 1992-04-08 1993-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Wild-type measles virus glycoproteins: vaccine and detection method therefor
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CN1152935A (zh) 1994-05-16 1997-06-25 麦克公司 乳头状瘤病毒疫苗
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
ES2216280T3 (es) 1997-04-08 2004-10-16 MERCK & CO., INC. Formulaciones estabilizadas de papilomavirus humano.
WO1998050071A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
SI1105466T1 (sl) 1998-08-14 2006-08-31 Merck & Co Inc Postopek za ciscenje virusu podobnih delcev humanega papilomskega virusa
AU770809B2 (en) 1998-12-17 2004-03-04 Merck Sharp & Dohme Corp. Synthetic virus-like particles with heterologous epitopes
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
CA2375337C (en) 1999-06-22 2012-09-25 Naokazu Takeda Srsv detection kit
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP2591771A1 (en) 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
ATE521367T1 (de) 2002-06-07 2011-09-15 Kentucky Bioproc Llc Flexlibler aufbau- und darreichungs-plattform von impfstoffen
EP1513552B1 (en) 2002-06-20 2010-12-01 Cytos Biotechnology AG Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use
EP1594536B1 (en) 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CA2593176A1 (en) 2005-01-05 2006-07-13 Peter D. Katsikis Delivery vehicles, bioactive substances and viral vaccines
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
US7767212B2 (en) 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
JP2009501001A (ja) 2005-06-01 2009-01-15 ダウ グローバル テクノロジーズ インコーポレイティド 多価ウイルス様粒子の製造
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
SG174845A1 (en) * 2006-09-29 2011-10-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
KR20150098681A (ko) * 2007-03-14 2015-08-28 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
WO2009033229A1 (en) 2007-09-12 2009-03-19 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
DK2324113T3 (en) * 2008-08-08 2018-04-16 Takeda Vaccines Inc VIRUS-LIKE PARTICLES INCLUDING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR INCREASED CRYSTAL REACTIVITY
EP2381959A1 (en) * 2009-01-22 2011-11-02 Pharmathene Inc. Stable vaccine compositions and methods of use
CN102438651A (zh) * 2009-02-10 2012-05-02 诺华有限公司 用于大流行相关毒株的流感疫苗方案
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CN102791286B (zh) 2010-01-21 2017-08-08 莱戈赛特医药股份有限公司 杯状病毒病毒样颗粒上靶定异源抗原的呈递
US20110293701A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
WO2013009849A1 (en) 2011-07-11 2013-01-17 Ligocyte Pharmaceuticals, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
FI3827838T3 (fi) 2015-12-16 2023-06-19 Walter & Eliza Hall Inst Medical Res Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa
GB2604416B (en) 2016-10-18 2023-03-15 Univ Minnesota Tumor infiltating lymphocytes and methods of therapy
KR20210005240A (ko) 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
JP2021534074A (ja) 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2020168300A1 (en) 2019-02-15 2020-08-20 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy

Also Published As

Publication number Publication date
EP4112074A1 (en) 2023-01-04
JP6613259B2 (ja) 2019-11-27
CA2841356A1 (en) 2013-01-17
US20230338503A1 (en) 2023-10-26
AU2012282658A1 (en) 2013-03-14
ES2926487T3 (es) 2022-10-26
JP6208659B2 (ja) 2017-10-04
EA201792407A3 (ru) 2018-07-31
PH12018501515A1 (en) 2019-02-04
EA035442B1 (ru) 2020-06-17
ZA201401012B (en) 2015-05-27
HK1215154A1 (zh) 2016-08-19
PH12018501515B1 (en) 2019-02-04
US20180185468A1 (en) 2018-07-05
MX2014000411A (es) 2014-08-26
ZA201500915B (en) 2016-06-29
DOP2014000004A (es) 2014-10-31
US11701420B2 (en) 2023-07-18
EA202090699A2 (ru) 2020-07-31
ECSP14013201A (es) 2014-05-31
CN105031637A (zh) 2015-11-11
MX356586B (es) 2018-06-05
AU2015200836A1 (en) 2015-03-12
SG10201605644WA (en) 2016-09-29
PL2731621T3 (pl) 2018-10-31
KR102096937B1 (ko) 2020-04-03
EA029470B1 (ru) 2018-03-30
AU2015200836B2 (en) 2016-08-25
CA2841356C (en) 2022-03-01
TN2014000008A1 (en) 2015-07-01
DOP2022000030A (es) 2022-06-30
EP2731621B1 (en) 2017-11-01
PL3299030T3 (pl) 2022-12-05
MY170746A (en) 2019-08-27
GEP201706668B (en) 2017-05-25
US9867876B2 (en) 2018-01-16
JP2014520852A (ja) 2014-08-25
CR20140069A (es) 2014-06-27
CN108567975A (zh) 2018-09-25
EP2731621A1 (en) 2014-05-21
EA201490258A1 (ru) 2014-05-30
HK1199202A1 (en) 2015-06-26
WO2013009849A1 (en) 2013-01-17
CL2014000082A1 (es) 2014-07-04
AU2012282658B2 (en) 2014-11-27
EA202090699A3 (ru) 2020-11-30
CN103874507A (zh) 2014-06-18
DK3299030T3 (da) 2022-09-05
US20160000899A1 (en) 2016-01-07
US20210085778A1 (en) 2021-03-25
KR20140066160A (ko) 2014-05-30
NZ710919A (en) 2017-12-22
HK1198136A1 (en) 2015-03-13
EP3299030B1 (en) 2022-06-08
UA117732C2 (uk) 2018-09-25
CR20190540A (es) 2022-04-04
US20130273102A1 (en) 2013-10-17
US9801934B2 (en) 2017-10-31
EP3299030A1 (en) 2018-03-28
EP2731621A4 (en) 2015-03-25
NZ620865A (en) 2015-08-28
US10675341B2 (en) 2020-06-09
IL230356B (en) 2019-05-30
EA201792407A2 (ru) 2018-03-30
JP2017214357A (ja) 2017-12-07
BR112014000656A2 (pt) 2017-02-14
MA35414B1 (fr) 2014-09-01
ES2656527T3 (es) 2018-02-27

Similar Documents

Publication Publication Date Title
PE20140845A1 (es) Formulaciones parenterales de vacunas contra los norovirus
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
AR061894A1 (es) Vacunas para malaria
EP2765138A3 (en) HIV-1 envelope glycoprotein
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
EA201492214A1 (ru) Ингибиторы вируса гепатита с
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
JP2013216685A5 (es)
EP2661278A4 (en) GENERATION OF ANTIBODIES AGAINST TUMOR ANTIGENS AND GENERATION OF CYTOTOXICITY DEPENDING ON THE SPECIFIC COMPONENT OF A TUMOR BY THE ADMINISTRATION OF ONCOLYTIC VACCINE VIRUS
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
EA201892735A1 (ru) Состав вакцины против hiv
EA201390810A1 (ru) Жидкие вирусные составы
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
EA201390812A1 (ru) Лиофилизированные вирусные составы
AR088907A1 (es) Vacuna
PE20221792A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
BR112012029633A2 (pt) vetores do parapoxvírus contendo antígeno do vírus da raiva.
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.

Legal Events

Date Code Title Description
FG Grant, registration